← State exam

100. Rectal carcinoma

High yield

MRI-staged rectal cancer is treated with TME surgery, neoadjuvant therapy when advanced, and watch-and-wait after complete response.

Exam Prep · State examSurgery · General surgerySurgery · ColorectalSurgery · Surgical oncology

1. Definition

  • Rectal carcinoma → malignant tumour of the rectum, over 90–95% adenocarcinoma
  • Rectal cancer by height → lower edge within 15 cm of the anal verge on rigid sigmoidoscopy (UK and many European guidelines: within 15 cm; some use 12 cm or the sigmoid take-off on MRI)
    • Low → 0–5 cm; middle → 5–10 cm; high → 10–15 cm
  • Differs from colon cancer in anatomy (pelvis, sphincters, nerves), local recurrence risk and the role of radiotherapy
  • Shared features with colon cancer (genetics, pathways, screening, chemotherapy) → question 86; anatomy and examination → question 99

2. Epidemiology

  • About 30–35% of colorectal cancers
  • Colorectal cancer → third most common cancer, second cause of cancer death
  • Men more than women (about 1.5 : 1)
  • Median age about 65–70; rising in under-50s (about 2% a year)
  • Local recurrence → 20–40% in the era before TME; now under 5–10% with TME and neoadjuvant treatment
  • 5-year survival → stage I about 90%, II about 75–80%, III about 60–70%, IV about 10–15%

3. Aetiology and risk factors

  • Same as colon cancer (question 86):
    • Age, male sex, family history
    • Diet → red and processed meat, low fibre; obesity, inactivity, smoking, alcohol, type 2 diabetes
    • Adenomas (adenoma–carcinoma sequence), especially large villous adenomas of the rectum
    • Inflammatory bowel disease (UC, Crohn's colitis), PSC
    • Hereditary → Lynch syndrome, FAP, MUTYH-associated polyposis
    • Previous pelvic radiotherapy (prostate cancer)
  • Molecular → mostly chromosomal instability (APC, KRAS, TP53); dMMR/MSI-high only about 2–5% of rectal cancers (much less than in the right colon)

4. Pathogenesis

Gross types

  • Ulcerative (most common) → ulcer with raised everted edges
  • Polypoid (cauliflower), annular (stenosing), diffusely infiltrating (linitis plastica-like, rare)
  • Mucinous (over 50% mucin) and signet ring → worse prognosis

Spread

  • Direct → through the wall into the mesorectum, then to adjacent organs (bladder, prostate, seminal vesicles, vagina, uterus, sacrum, pelvic side walls)
    • Distal intramural spread is usually under 1 cm (basis of the 1 cm distal margin rule)
  • Lymphatic:
    • Upward along the superior rectal vessels to the inferior mesenteric nodes (main route; contained in the mesorectum)
    • Lateral → internal iliac and obturator nodes for low tumours below the peritoneal reflection
    • Downward to inguinal nodes → only if the tumour invades the anal canal below the dentate line
  • Venous → superior rectal vein → portal vein → liver (most common); middle and inferior rectal veins → systemic → lungs (lung metastases more common than in colon cancer)
    • Extramural venous invasion (EMVI) on MRI → high risk of distant spread
  • Transcoelomic → peritoneum (upper rectum)
  • Implantation → anastomosis, wounds

Circumferential resection margin (CRM)

  • The distance from the tumour to the mesorectal fascia (the surgical plane)
  • CRM involved (1 mm or less) → high local recurrence and worse survival → key target of MRI staging and surgery

5. Classification

TNM (AJCC/UICC 8th edition)

  • Tis → intramucosal carcinoma
  • T1 → submucosa; T2 → muscularis propria; T3 → through the muscle into the mesorectal fat (T3a under 1 mm, T3b 1–5 mm, T3c 5–15 mm, T3d over 15 mm on MRI); T4a → visceral peritoneum; T4b → other organs
  • N1 → 1–3 nodes (N1c: tumour deposits); N2 → 4 or more
  • M1a → one organ; M1b → more than one; M1c → peritoneum

Stage groups

  • I → T1–2 N0; II → T3–4 N0; III → any T N1–2; IV → M1
  • Dukes → A (wall), B (through the wall, N0), C (nodes), D (distant; Turnbull)

MRI risk groups (ESMO)

  • Very early → T1 sm1–2 N0 → local excision
  • Early ("good") → T1–T2, T3a–b, N0–N1 (high rectum), CRM clear, no EMVI → TME alone
  • Intermediate ("bad") → T3 (mid or low), N1–N2, CRM clear, no EMVI → short-course RT or chemoradiotherapy, or TME alone in selected cases
  • Locally advanced ("ugly") → CRM threatened or involved, T4, EMVI positive, lateral nodes, low tumours involving the levators → neoadjuvant chemoradiotherapy or total neoadjuvant therapy (TNT)

Pathology quality (Quirke)

  • Mesorectal plane (complete, smooth) → best
  • Intramesorectal plane (nearly complete)
  • Muscularis propria plane (incomplete, defects to the muscle) → higher recurrence

Response to neoadjuvant treatment

  • Clinical complete response (cCR) → no tumour on DRE, endoscopy (white scar) or MRI
  • Pathological complete response (pCR) → no tumour in the specimen (ypT0N0); about 15–20% after CRT, up to about 28% after TNT
Grid of rectal cancer MRI risk groups and treatment
Diagram: rectal cancer MRI risk groups with the usual treatment for each

6. Clinical picture

Symptoms

  • Rectal bleeding → most common; dark or bright red, mixed with stool or on the surface
  • Change in bowel habit → frequent, loose or constipated stools, spurious diarrhoea
  • Tenesmus (feeling of incomplete emptying), early morning bloody diarrhoea, mucus
  • Pain → late (invasion of the sphincters or sacral nerves; perineal or sciatic pain)
  • Obstruction → narrow stools, colic, distension (large or annular tumours)
  • Urinary symptoms, pneumaturia (bladder invasion: fistula), vaginal discharge of faeces
  • Weight loss, anorexia, fatigue (anaemia)
  • Metastases → hepatomegaly, jaundice, cough

Signs

  • DRE → hard, irregular, ulcerated mass with raised edges; note height from the anal verge, size, circumference involved, mobility or fixity, relation to the sphincters and prostate or vagina; blood on the glove
  • Anaemia, abdominal distension, hepatomegaly, ascites
  • Inguinal nodes (very low tumours)
  • Blumer's shelf (pouch of Douglas deposits)

7. Diagnosis

Confirm

  • DRE and rigid sigmoidoscopy (exact height)
  • Colonoscopy with biopsy → histology; synchronous tumours (3–5%) and polyps; tattoo for surgery
  • If colonoscopy is incomplete → CT colonography

Local staging

  • High-resolution pelvic MRI → imaging of choice:
    • T stage, depth of extramural spread (mm)
    • CRM (distance to the mesorectal fascia; threatened if 1 mm or less, some use 2 mm)
    • Nodes (mesorectal and lateral), tumour deposits
    • EMVI
    • Height, relation to the peritoneal reflection, levators and sphincters (low rectal tumours)
    • Restaging after neoadjuvant treatment (tumour regression grade; diffusion-weighted imaging)
  • Endorectal ultrasound (ERUS) → early tumours (T1 vs T2, submucosal depth) for local excision; less useful for advanced tumours

Distant staging

  • CT chest, abdomen and pelvis with contrast → liver and lung metastases
  • MRI liver (indeterminate lesions), PET-CT (selected: suspected recurrence, before major resection of metastases)

Bloods and markers

  • CEA (baseline), FBC, LFT, U&E
  • MMR or MSI testing of every tumour (Lynch screening; dMMR tumours respond to immunotherapy)
  • RAS, BRAF (metastatic disease)

Function and fitness

  • Baseline continence, urinary and sexual function, frailty, comorbidity, stoma counselling and siting

Multidisciplinary team (MDT)

  • Every patient discussed before treatment and after restaging
Flowchart for the management of rectal cancer
Diagram: rectal cancer, from MRI staging to surgery, neoadjuvant treatment or watch-and-wait

8. Differential diagnosis

  • Benign → large villous adenoma, solitary rectal ulcer syndrome, inflammatory polyp, endometriosis, stercoral ulcer
  • Inflammatory → proctitis (UC, Crohn's, radiation), STI proctitis (LGV), amoebiasis
  • Other tumours → anal squamous cell carcinoma (different treatment: chemoradiotherapy), rectal neuroendocrine tumour, GIST, lymphoma, melanoma, prostate cancer invading the rectum, presacral tumours
  • Haemorrhoids and fissure (common cause of bleeding, but must not be assumed)
  • Diverticular stricture (rectosigmoid)

9. Treatment

Conservative

  • Neoadjuvant treatment → for intermediate and locally advanced tumours (mid and low rectum):
    • Short-course radiotherapy (SCRT) → 5 × 5 Gy over 1 week, then surgery within 1 week, or delayed surgery after 4–8 weeks (Swedish, Dutch TME, Stockholm III trials)
    • Long-course chemoradiotherapy (LCCRT) → 45–50.4 Gy in 25–28 fractions over 5 weeks with capecitabine or 5-FU; surgery at 8–12 weeks (allows downstaging; German CAO/ARO/AIO-94: lower local recurrence than postoperative CRT, 6% vs 13%)
    • Total neoadjuvant therapy (TNT) → all chemotherapy and radiotherapy before surgery:
      • RAPIDO → SCRT then 6 cycles of CAPOX or 9 of FOLFOX → fewer treatment failures (23.7% vs 30.4%), pCR 28% vs 14%
      • PRODIGE-23 → FOLFIRINOX then CRT → better disease-free survival, pCR 27.8% vs 12.1%
      • OPRA → CRT then consolidation chemotherapy → more organ preservation (about 53%)
      • Now a standard option for locally advanced rectal cancer (NCCN, ESMO)
    • Neoadjuvant chemotherapy alone (selected; PROSPECT trial: FOLFOX with selective CRT, non-inferior for intermediate tumours in the upper and mid rectum)
  • Organ preservation ("watch-and-wait"):
    • After clinical complete response to CRT or TNT (no mass on DRE, flat white scar with telangiectasia on endoscopy, no tumour on diffusion-weighted MRI)
    • Habr-Gama: 5-year survival 100% and disease-free survival 92% in the first series
    • Regrowth in about 25–30%, mostly in the first 2 years, usually salvageable by surgery
    • Close follow-up → DRE, endoscopy and CEA every 3–6 months, MRI every 6 months, CT every 6–12 months for 2 years, then less often for 5 years
  • dMMR/MSI-high rectal cancer → neoadjuvant immunotherapy (dostarlimab or other PD-1 inhibitors): 100% clinical complete response in the first trial (Cercek 2022); avoids radiotherapy and surgery in many (emerging standard)
  • Adjuvant chemotherapy → after surgery for high-risk pathology (ypN+), if not given before (CAPOX or FOLFOX)
  • Metastatic disease → systemic chemotherapy ± biologics (anti-EGFR in RAS wild-type, bevacizumab), immunotherapy for dMMR; resection of liver or lung metastases if possible; radiotherapy to the primary for symptoms
  • Palliation → stent (upper rectum), defunctioning stoma, laser or argon plasma coagulation, radiotherapy for bleeding or pain, palliative care

Surgical

  • Principles:
    • Total mesorectal excision (TME, Heald 1982) → sharp dissection in the "holy plane" between the mesorectal fascia and the presacral fascia, removing the whole mesorectum intact (with its nodes) → local recurrence under 5–10%
    • Partial mesorectal excision (PME) → upper rectal tumours; divide the mesorectum 5 cm below the tumour at right angles (no coning)
    • Margins → distal 1 cm enough for low tumours after neoadjuvant treatment (2 cm without), CRM over 1 mm
    • High or low tie of the inferior mesenteric artery; splenic flexure mobilisation for a tension-free anastomosis
    • Preserve the hypogastric nerves and pelvic plexus (bladder and sexual function)
  • Operations:
    • Anterior resection (AR) → high AR (upper rectum, anastomosis above the peritoneal reflection) or low AR with TME (mid and low rectum); stapled colorectal or coloanal anastomosis; colonic J-pouch or side-to-end anastomosis for low ones (better function); defunctioning loop ileostomy for low anastomoses (closed at about 3 months)
    • Ultra-low AR with intersphincteric resection (ISR) and hand-sewn coloanal anastomosis → very low tumours not invading the external sphincter (good continence needed)
    • Abdominoperineal resection (APR, Miles 1908) → rectum, anal canal and sphincters removed with a permanent end colostomy; for tumours invading the sphincters or levators, poor continence, or where a clear distal margin cannot be achieved; extralevator APR (ELAPE) reduces positive margins and perforation
    • Hartmann's procedure → frail, obstructed or perforated cases, or poor sphincter function
    • Pelvic exenteration → T4b tumours invading the bladder, prostate, uterus or sacrum, and locally recurrent disease → en bloc multivisceral resection for R0 (specialist centres)
  • Access → laparoscopic (COREAN and other trials: similar oncological results to open), robotic (ROLARR; better in narrow male pelvis, lower conversion), transanal TME (taTME) (bottom-up dissection; selected centres after concerns about urethral injury and multifocal recurrence)
  • Local excision → TEM, TAMIS (full-thickness, en bloc):
    • Early T1 (sm1, maybe sm2), under 3 cm, well differentiated, no lymphovascular invasion, under 30% of the circumference
    • Also after a good response to neoadjuvant treatment in selected patients (organ preservation)
    • Completion TME if pathology shows high-risk features
  • Obstructing rectal cancer → defunctioning loop colostomy (or ileostomy), then staging and neoadjuvant treatment, then resection
  • ERAS (enhanced recovery), prehabilitation, correction of anaemia, mechanical bowel preparation + oral antibiotics, stoma marking

Follow-up

  • CEA every 3–6 months and CT chest, abdomen and pelvis at intervals for 3–5 years; colonoscopy at 1 year, then every 3–5 years; pelvic MRI in watch-and-wait

10. Complications

Of the disease

  • Obstruction, perforation, bleeding, fistula (rectovesical, rectovaginal)
  • Local recurrence → pelvic pain, bleeding, obstruction
  • Liver and lung metastases

Of surgery

  • Anastomotic leak → about 5–15% after low AR (higher in men, low anastomoses, after radiotherapy, smokers); diverting ileostomy reduces its severity
  • Low anterior resection syndrome (LARS) → frequency, urgency, clustering, incontinence in up to 60–80% (worse after radiotherapy and low anastomoses); treat with diet, loperamide, transanal irrigation, sacral nerve stimulation, stoma
  • Bladder dysfunction and sexual dysfunction (erectile and ejaculatory problems, dyspareunia) → pelvic nerve injury
  • Perineal wound problems after APR (infection, breakdown, hernia; flap reconstruction after ELAPE)
  • Stoma complications, high-output ileostomy (dehydration, AKI)
  • Ureteric injury, presacral venous bleeding (difficult to control: pressure, thumbtacks, muscle welding)
  • Urethral injury (taTME)

Of radiotherapy and chemotherapy

  • Radiation → proctitis, enteritis, fistula, pelvic insufficiency fractures, infertility, ovarian failure, second cancers, worse bowel function
  • Chemotherapy → oxaliplatin neuropathy, capecitabine hand-foot syndrome, DPD deficiency toxicity

Prognosis

  • Depends on stage, CRM status, quality of the TME specimen, EMVI, response to neoadjuvant treatment
  • Positive CRM → local recurrence over 20%; complete mesorectal specimen → under 5%

Mind map Pinch or scroll to zoom · drag to move

Show as a list

Rectal carcinoma

  • Basics
    • Within 15 cm of verge
    • Low, mid, high
    • Adenocarcinoma
  • Spread
    • Mesorectum
    • Lateral nodes if low
    • Portal + systemic veins
    • CRM key
  • Staging
    • DRE, rigid scope
    • Colonoscopy, biopsy
    • Pelvic MRI: CRM, EMVI
    • CT chest-abdomen-pelvis
    • MMR testing
  • Neoadjuvant
    • SCRT 5x5 Gy
    • CRT 50 Gy + capecitabine
    • TNT: RAPIDO, PRODIGE
    • dMMR: dostarlimab
  • Surgery
    • TME: holy plane
    • Low AR + ileostomy
    • APR if sphincters
    • TEM/TAMIS: early T1
  • Watch and wait
    • cCR
    • Regrowth 25-30%
    • Close surveillance
  • Complications
    • Leak
    • LARS
    • Nerve injury

More in State exam